The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 02, 2025

Filed:

Oct. 22, 2020
Applicant:

Seoul National University R&db Foundation, Seoul, KR;

Inventors:

Jae Min Jeong, Seoul, KR;

Nadeem Ahmed Lodhi, Seoul, KR;

Yun-Sang Lee, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07F 13/00 (2006.01); C07B 59/00 (2006.01);
U.S. Cl.
CPC ...
C07F 13/005 (2013.01); C07B 59/004 (2013.01); A61K 2121/00 (2013.01); A61K 2123/00 (2013.01); C07B 2200/05 (2013.01);
Abstract

The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitrile are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagnosing prostate cancer, containing the derivative as an active ingredient. A derivative according to the present invention has high binding capacity for PSMA, which is expressed in prostate cancer, by acting as a multi-ligand through the binding of three or six derivatives to one atom of technetium or rhenium, has excellent stability in human serum when administered in vivo, and is excreted into the kidney rather than the hepatobiliary tract because of high water solubility so that a clear image of a prostate cancer tumor site can be obtained, and thus the present invention can be effectively usable as a pharmaceutical composition for treating or diagnosing prostate cancer.


Find Patent Forward Citations

Loading…